Screener
Nuvectis Pharma, Inc. NVCT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Decrease in employee compensation and benefits | (460) | (519) |
| Net cash used in operating activities | $(6,511) | $(4,174) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Net cash provided by (used in) investing activities | — | — |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of common shares - At-the market offering | $7 | $1,273 |
| Issuance costs related to At-the-market offering | — | (41) |
| Proceeds from public offering | — | 15,525 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s investing cash flow?
- Nuvectis Pharma, Inc. (NVCT) reported investing cash flow of $0 in Q1 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Nuvectis Pharma, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude